A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study

Status Completed

Clinical Trial Summary

The purpose of this research study is to investigate the safety and tolerability of OP-1 when it is injected into the knee joint of patients who have osteoarthritis on the knee.

Clinical Trial Description

Subjects with OA will be recruited and informed consent obtained. During a screening period lasting 1 to 28 days, subjects will undergo medical and arthritis history, physical examination, collection of concomitant medications, KOOS (which contains the WOMAC questionnaire), SF-36 and global 100 mm VAS assessments, have samples obtained for urinalysis, hematology, chemistry, immunology and serum and plasma for future biomarker testing, ECG, bilateral knee x-rays and MRI of the index knee at selected sites. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be randomized into the first cohort of 8 subjects to receive either 1.0 mL lactose (placebo) (2 subjects) or 1.0 mL OP-1 (6 subjects) intraarticularly using ultrasound or fluoroscopy guidance in an outpatient setting on day 1. Each cohort will consist of 8 treated patients, with treatment allocation in a 3:1 active-to-lactose (placebo) ratio. After an observation period of at least one hour, subjects will be released and contacted via telephone on Day 2 to query for AEs and concomitant medications. Additional follow-up visits will be done on days 7, 14, 28, 56, 84 and 168 (weeks 1, 2, 4, 8, 12 and 24) and safety and efficacy parameters evaluated according to the Schedule of Events. When a minimum of 4 weeks have elapsed since the last patient of the current cohort has been treated, all safety data will be collected and reviewed by the Principal Investigators and the Sponsor. The safety review will be conducted to ensure the demonstrated safety profile of OP-1 is acceptable for the treated patients. Only after the current dose level has been judged to be safe will dose escalation to the next dosing cohort occur. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00456157
Study type	Interventional
Source	Stryker Biotech
Contact
Status	Completed
Phase	Phase 1
Start date	March 2007
Completion date	November 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03277066` - A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis	Phase 2
Recruiting	`NCT03090698` - Outcomes of Injections in Patients Waiting for Total Knee Replacement	Phase 4
Completed	`NCT02556710` - A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee	Phase 3
Completed	`NCT02242435` - A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis	Phase 3
Withdrawn	`NCT02237846` - Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis	Phase 1/Phase 2
Completed	`NCT01849445` - Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study	N/A
Completed	`NCT02096393` - Patient Specific Instrumentation in TKR	N/A
Completed	`NCT01704157` - A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device	N/A
Active, not recruiting	`NCT01374230` - Long-Term Multicenter Evaluation of the E1® Tibial Bearing	N/A
Completed	`NCT01410409` - Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement	N/A
Not yet recruiting	`NCT01270412` - Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis	Phase 2/Phase 3
Completed	`NCT02156440` - Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee	Phase 2
Completed	`NCT01207115` - A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee	Phase 2
Completed	`NCT00970008` - Exploring Massage Benefits for Arthritis of the Knee	Phase 2
Completed	`NCT01331278` - A Comparative Study of Knee Systems	Phase 4
Completed	`NCT00988091` - Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee	Phase 3
Completed	`NCT00531427` - Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee	Phase 3
Completed	`NCT00792727` - HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain	Phase 3
Completed	`NCT00449696` - Gel-200 Versus Placebo in Osteoarthritis of the Knee	Phase 3
Completed	`NCT04145011` - Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee — Knee OA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms